Multimorbidity in Obesity: An Evidence-Based Case Report

✓

Key Takeaways

Recognize the bidirectional metabolic and cardiovascular interplay between obesity, T2DM, and hypertension.
Apply the STOP-BANG questionnaire to risk-stratify patients for obstructive sleep apnea.
Evaluate pharmacologic interactions and adverse metabolic effects in multimorbidity.
Construct an evidence-based, prioritized problem list with current guideline-directed management.

Learning Objectives

By the end of this case, the reader should be able to:

Recognize the bidirectional metabolic and cardiovascular interplay between obesity, T2DM, and hypertension.
Apply the STOP-BANG questionnaire to risk-stratify patients for obstructive sleep apnea.
Evaluate pharmacologic interactions and adverse metabolic effects in multimorbidity.
Construct an evidence-based, prioritized problem list with current guideline-directed management.
Apply USPSTF and CDC/ACIP screening and vaccination recommendations to a complex chronic disease patient.

Patient Information

Demographics & Visit Context

Parameter	Details
Age / Sex	50-year-old female
Occupation	Housewife
Parity	G5P5
Reason for Visit	Scheduled follow-up — chronic disease management

History

Chief Complaint

Follow-up for type 2 diabetes mellitus, hypertension, and post-traumatic epilepsy.

History of Present Illness

A 50-year-old obese female (BMI 39.7 kg/m²) presents for scheduled follow-up of multiple chronic conditions. She was diagnosed with type 2 diabetes mellitus (T2DM) several years ago and is currently on premixed insulin 70/30. Despite insulin therapy, glycemic control remains suboptimal with HbA1c 8.2%, above the ADA target of <7.0% for most non-pregnant adults.¹ Blood pressure today is 150/89 mmHg, exceeding the ADA-recommended target of <130/80 mmHg in patients with diabetes and cardiovascular risk factors.¹,² She has post-traumatic epilepsy currently managed with sodium valproate with no recent breakthrough seizures. She was started on escitalopram and bromazepam for anxiety and insomnia. She endorses habitual snoring but denies witnessed apneas or excessive daytime somnolence.

Past Medical History

Type 2 Diabetes Mellitus — on insulin therapy
Hypertension — on losartan
Post-Traumatic Epilepsy — on sodium valproate
Anxiety / insomnia — on escitalopram and bromazepam
Obesity (Class II, BMI 39.7 kg/m²)

Medications

Current Medication List

Medication	Dose / Frequency	Indication	Notable Concerns
Insulin 70/30 (NPH/Regular)	35 units SC QAM; 40 units SC QPM	T2DM	Fixed ratio limits flexibility; may need basal-bolus conversion
Losartan	50 mg PO daily	Hypertension	Undertitrated; max dose 100 mg/day
Sodium Valproate	500 mg PO BID	Post-traumatic epilepsy	Associated with weight gain and insulin resistance
Escitalopram	20 mg PO at bedtime	Anxiety / depression	Monitor QTc if adding other agents
Bromazepam	3 mg PO at bedtime	Insomnia / anxiety	CONTRAINDICATED in suspected OSA; respiratory depression risk

Allergies

No known drug allergies.

Family History

Obesity and type 2 diabetes mellitus — maternal side
No known family history of seizure disorder or premature cardiovascular disease

Social History

Housewife; mother of five children; predominantly sedentary lifestyle.
No tobacco, alcohol, or illicit drug use.
Dietary habits not formally assessed; medical nutrition therapy (MNT) not previously initiated.

Review of Systems

Positive: snoring, fatigue, persistently elevated home blood pressure.
Negative: no witnessed apneas, no excessive daytime somnolence, no polyuria / polydipsia, no chest pain, no palpitations, no focal neurological symptoms, no recent seizures, no melena, no hematuria.

Physical Examination

Vital Signs

Vitals & Anthropometrics with Guideline Targets

Parameter	Value	Guideline Target / Reference
Blood Pressure	150/89 mmHg	<130/80 mmHg (ADA 2025, AHA/ACC 2024)¹,²
Heart Rate	87 bpm	60–100 bpm
Respiratory Rate	15 /min	12–20 /min
Temperature	37.0 °C	Normal
Weight / Height	108 kg / 165 cm	—
BMI	39.7 kg/m² (Class II Obesity)	Class I ≥30; Class II ≥35 (WHO/NHLBI)³
Neck Circumference	38 cm	OSA risk threshold: >40 cm (F), >43 cm (M)

Examination Findings

General: Alert, oriented x3, obese female in no acute distress.
Cardiovascular: Regular rate and rhythm. No murmurs, rubs, or gallops. No peripheral edema. Peripheral pulses 2+ bilaterally.
Respiratory: Clear to auscultation bilaterally. No wheezes, rhonchi, or crackles.
Abdomen: Obese, soft, non-tender, no hepatosplenomegaly.
Neurological: GCS 15/15. No focal motor or sensory deficits. Cranial nerves II–XII grossly intact.
Extremities / Skin: No foot ulcers; intact sensation to monofilament testing not documented — order at this visit. No acanthosis nigricans documented.

STOP-BANG Questionnaire for OSA Screening

The STOP-BANG questionnaire is a validated, 8-item tool with sensitivity of 93% and specificity of 36% for moderate-to-severe OSA at a cutoff score ≥3.⁴

STOP-BANG Items, Responses & Scoring

Item	Response	Score
S — Snoring loudly	Yes	1
T — Tired / sleepy most days	No	0
O — Observed apnea	No	0
P — Pressure (hypertension treated or BP >140/90)	Yes	1
B — BMI >35 kg/m²	Yes (BMI 39.7)	1
A — Age >50 years	Yes (age 50, borderline)	1
N — Neck circumference >40 cm	No (38 cm)	0
G — Gender male	No	0
TOTAL	4 / 8 — INTERMEDIATE RISK
Interpretation: 0–2 = low risk; 3–4 = intermediate risk; 5–8 = high risk. Score ≥3 warrants further evaluation with polysomnography or home sleep apnea test per AASM guidelines.⁴,⁵

Clinical Context

STOP-BANG ≥3 in a patient already on a benzodiazepine is a red flag — bromazepam reduces upper airway muscle tone and blunts the arousal response to hypoxia, magnifying OSA-related cardiometabolic risk until objective sleep testing is completed.

Diagnostic Studies

Laboratory Results

Initial Laboratory Panel

Test	Result	Reference	Interpretation
Hemoglobin	10.8 g/dL	12.0–16.0 g/dL	Mild anemia — workup required
Hematocrit	32%	36–46%	Low
WBC	7.2 ×10⁹/L	4.5–11.0 ×10⁹/L	Normal
Platelets	230 ×10⁹/L	150–400 ×10⁹/L	Normal (monitor on valproate)
Random Glucose	191 mg/dL	<140 mg/dL (2-hr PP)	Elevated
HbA1c	8.2%	<7.0% (ADA 2025 target)¹	Suboptimal glycemic control
Total Bilirubin	0.4 mg/dL	0.2–1.2 mg/dL	Normal
ALT	38 U/L	7–56 U/L	High-normal; monitor for MASLD
AST	35 U/L	10–40 U/L	Normal
Creatinine	0.6 mg/dL	0.5–1.1 mg/dL	Normal; eGFR adequate

Additional Studies Ordered / Recommended

Fasting lipid panel — ASCVD risk stratification; statin initiation likely indicated per ADA 2025 and ACC/AHA Pooled Cohort Equations.¹,²
Urine albumin-to-creatinine ratio (UACR) + eGFR — annual DKD screening per ADA Standards of Care 2025.¹
Dilated funduscopic exam — annual diabetic retinopathy screen per ADA 2025.¹
10-g monofilament foot exam — annual peripheral neuropathy screen per ADA 2025.¹
Iron studies, reticulocyte count, peripheral smear, B12, folate, TSH — anemia workup; exclude valproate-associated cytopenias.
Home sleep apnea test (HSAT) or polysomnography — per AASM 2023 clinical practice guidelines given STOP-BANG ≥3 and benzodiazepine use.⁵
Fasting lipid panel, LFTs, serum valproate level — annual monitoring per neurology guidelines.
PHQ-9 and GAD-7 — depression and anxiety screening per USPSTF Grade B recommendations.⁶

Differential Diagnosis (Prioritized)

1. Poorly Controlled Type 2 Diabetes Mellitus

Most likely and confirmed diagnosis. HbA1c 8.2% reflects persistent hyperglycemia above the individualized ADA 2025 target of <7.0%.¹ Contributing drivers include: obesity-mediated insulin resistance, premixed insulin limitations, medication effects (sodium valproate), dietary non-adherence, sedentary lifestyle, and possible undiagnosed OSA exacerbating insulin resistance via intermittent hypoxia and sympathetic overactivation.⁷

2. Uncontrolled Hypertension

BP 150/89 mmHg despite ARB therapy. Per the 2024 AHA/ACC Hypertension Guideline, target BP in patients with T2DM is <130/80 mmHg.² Differential includes: losartan undertitration (currently at half the maximum dose), obesity-driven sympathetic overactivation and RAAS upregulation,⁸ and possible contribution from untreated OSA causing nocturnal and sustained hypertension.⁷

3. Intermediate-Risk Obstructive Sleep Apnea

STOP-BANG 4/8 with snoring, BMI >35, hypertension, and age ≥50. OSA affects approximately 34% of middle-aged men and 17% of middle-aged women, with higher prevalence in obese individuals.⁹ The absence of witnessed apneas does not exclude OSA; subclinical or mild-moderate disease is clinically relevant given its bidirectional relationship with insulin resistance, hypertension, and cardiovascular risk.⁷ Bromazepam use is an additional red flag, as benzodiazepines reduce upper airway muscle tone and blunt the arousal response to hypoxia.¹⁰

4. Medication-Induced Metabolic Dysregulation

Sodium valproate promotes weight gain (estimated 4–8 kg average) and induces insulin resistance through PPAR-γ activation and hyperinsulinemia mechanisms.¹¹ This may be a significant contributor to both suboptimal glycemic control and worsening obesity in this patient.

5. Mild Anemia — Etiology Undetermined

Hgb 10.8 g/dL. Differential includes iron deficiency anemia (most prevalent in women of this age group), anemia of chronic disease (T2DM, chronic inflammation), B12 or folate deficiency, or valproate-associated hematologic effects including thrombocytopenia or aplastic anemia (rare).¹²

6. Metabolic-Associated Steatotic Liver Disease (MASLD)

Formerly NAFLD/NASH; renamed per 2023 Delphi consensus. MASLD is present in up to 55–75% of patients with T2DM and obesity.¹³ Borderline ALT (38 U/L) and AST (35 U/L) in this metabolic context warrant monitoring. Fibrosis-4 (FIB-4) index should be calculated per 2023 AASLD guidance.¹³

Prioritized Problem List & Management Plan

Problem 1: Poorly Controlled T2DM (HbA1c 8.2%)

Assessment. The ADA Standards of Medical Care in Diabetes 2025 recommends HbA1c <7.0% for most non-pregnant adults, with individualization based on comorbidities.¹ In obese patients, GLP-1 receptor agonists (GLP-1 RAs) are now the preferred add-on agents due to weight loss benefit, cardiovascular risk reduction, and demonstrated HbA1c lowering of 1.0–1.8%.¹,¹⁴

Plan:

Insulin titration: Increase 70/30 dose by 2 units every 3 days if fasting glucose >130 mg/dL (ADA 2025 insulin titration protocol).¹
Add GLP-1 receptor agonist: Initiate semaglutide (Ozempic) 0.25 mg SQ weekly, titrating to effect. The SUSTAIN-6 trial demonstrated significant HbA1c reduction (1.1%) and 26% reduction in MACE vs. placebo in T2DM patients with high CV risk.¹⁴ Semaglutide also produces ~5–6 kg weight loss, beneficial in this patient.
Consider SGLT-2 inhibitor: Empagliflozin or dapagliflozin if eGFR ≥30 mL/min. EMPA-REG OUTCOME showed 38% reduction in CV death and 32% reduction in renal progression in T2DM with CVD.¹⁵
Medical nutrition therapy (MNT): Refer to registered dietitian for individualized meal planning per ADA 2025 and Academy of Nutrition and Dietetics guidelines.¹
Physical activity: Target ≥150 min/week moderate-intensity aerobic exercise per ADA/ACC recommendations; resistance training ≥2×/week.¹
Monitoring: Repeat HbA1c in 3 months; annual UACR, eGFR, fasting lipids, foot and eye exams per ADA Standards.¹

Problem 2: Uncontrolled Hypertension (150/89 mmHg)

Assessment. Per the 2024 AHA/ACC Hypertension Guidelines, BP target in T2DM patients is <130/80 mmHg to reduce risk of stroke, MI, and CKD progression.² Losartan at 50 mg daily is undertitrated (maximum dose 100 mg/day). ARBs remain the preferred first-line agent in T2DM due to nephroprotective properties validated in the RENAAL and IDNT trials.¹⁶

Plan:

Uptitrate losartan: Increase to 100 mg PO daily. Re-check BP and basic metabolic panel (BMP) in 2–4 weeks.²
Add amlodipine 5 mg: If BP remains >130/80 mmHg after uptitration, add a dihydropyridine CCB. Per ACCOMPLISH, ARB + CCB combination was superior to ARB + diuretic for cardiovascular outcomes.¹⁷
OSA treatment: CPAP therapy in confirmed OSA reduces systolic BP by approximately 2–3 mmHg and has disproportionately greater effect on nocturnal and resistant hypertension.⁷
Lifestyle: Sodium restriction <2,300 mg/day, DASH dietary pattern, weight loss (5 kg weight reduction lowers systolic BP by ~5 mmHg).²

Safety Warning

Bromazepam is contraindicated in suspected or confirmed OSA. Continuing it while uptitrating antihypertensives risks unmasking nocturnal hypoxemia and worsening resistant hypertension — taper before initiating CPAP titration.

Problem 3: Intermediate-Risk Obstructive Sleep Apnea (STOP-BANG 4/8)

Assessment. OSA is present in ~40–60% of patients with T2DM and worsens both insulin resistance and blood pressure via intermittent hypoxia, sympathetic activation, and systemic inflammation.⁷,⁹ The 2023 AASM Clinical Practice Guidelines recommend objective sleep testing for all patients with intermediate or high STOP-BANG scores.⁵ Benzodiazepine use (bromazepam) in this context is a significant safety concern, as these agents reduce upper airway muscle tone and suppress hypoxic ventilatory response.¹⁰

Plan:

Order home sleep apnea test (HSAT): Per AASM 2023, HSAT is appropriate for uncomplicated suspected OSA without significant cardiorespiratory comorbidity. Refer to sleep medicine if HSAT is inconclusive or if central apnea is suspected.⁵
Discontinue bromazepam: Taper gradually over 4–8 weeks to prevent withdrawal. Benzodiazepines are contraindicated in OSA per AASM.¹⁰
First-line insomnia treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for chronic insomnia per the 2021 ACP and 2023 AASM guidelines.¹⁸
If OSA confirmed, initiate CPAP: CPAP is standard of care for moderate-to-severe OSA per AASM. Meta-analyses confirm modest improvements in blood pressure, insulin sensitivity, and quality of life.⁵,⁷

Problem 4: Post-Traumatic Epilepsy (No Recent Seizures)

Assessment. Currently seizure-free on sodium valproate 500 mg BID. Valproate is a broad-spectrum AED effective for generalized and focal seizures; however, it is associated with weight gain (mean +4.8 kg), insulin resistance, hyperammonemia, thrombocytopenia, and hepatotoxicity.¹¹,¹⁹ These metabolic side effects are particularly problematic in this patient.

Plan:

Maintain valproate: Continue current dose given seizure-free status. Do not alter AED without neurology guidance.
Neurology referral: Discuss transition to a weight-neutral or weight-reducing AED (e.g., lamotrigine, levetiracetam, topiramate). Topiramate has been associated with weight loss but has cognitive side effects; decision must balance seizure control vs. metabolic benefit.¹⁹
Monitoring: Annual CBC, LFTs, serum valproate trough levels, and ammonia if symptomatic. Platelet count today given anemia.

Problem 5: Mild Anemia (Hgb 10.8 g/dL)

Plan:

Anemia workup: Iron studies (serum ferritin, serum iron, TIBC), reticulocyte count, peripheral blood smear, B12, folate, TSH, and valproate drug level.¹²
If iron deficiency confirmed: Initiate ferrous sulfate 325 mg PO daily or BID with vitamin C to enhance absorption. Recheck CBC in 4–8 weeks.
FIB-4 index: Calculate to risk-stratify for MASLD-related fibrosis per 2023 AASLD/AGA guidance.¹³

Problem 6: Anxiety / Insomnia (Escitalopram + Bromazepam)

Assessment. Escitalopram 20 mg is appropriate for generalized anxiety disorder (GAD) and major depressive disorder (MDD), consistent with APA 2023 and CANMAT 2023 guidelines.²⁰ Bromazepam poses risk of respiratory depression in OSA, physical dependence, cognitive impairment, and fall risk. The 2023 AASM guidelines list benzodiazepine receptor agonists as agents to avoid in suspected or confirmed OSA.¹⁰,¹⁸

Plan:

Taper and discontinue bromazepam: Reduce by 25% every 1–2 weeks. Monitor for withdrawal symptoms (anxiety, tremor, insomnia rebound, seizure risk).¹⁰
CBT-I: First-line for chronic insomnia per ACP 2016 and AASM 2021; superior to pharmacotherapy at 12-month follow-up.¹⁸
If pharmacotherapy needed: Low-dose doxepin (3–6 mg) — FDA-approved for sleep maintenance insomnia, no respiratory depression risk. Ramelteon is an alternative melatonin agonist.
Continue escitalopram: Reassess depression / anxiety scores (PHQ-9, GAD-7) at each visit.⁶

Consults

Specialty Referrals & Goals

Specialty	Indication / Goal
Endocrinology	Insulin optimization; GLP-1 RA initiation; SGLT-2 inhibitor consideration; metabolic syndrome management
Sleep Medicine	OSA evaluation — HSAT/PSG per AASM 2023; CPAP initiation if indicated
Neurology	Valproate reassessment; weight-neutral AED consideration; seizure monitoring
Registered Dietitian	Medical nutrition therapy (MNT); ADA-consistent meal planning; caloric deficit for weight reduction
Behavioral Health / Psychology	CBT-I for insomnia; anxiety / depression management; DSMES participation
Ophthalmology	Annual dilated funduscopic exam per ADA 2025 — diabetic retinopathy screening
Podiatry	Annual comprehensive foot exam — monofilament testing, ABI if indicated
Nephrology (if indicated)	If UACR >300 mg/g or progressive eGFR decline despite maximum ARB therapy

Patient Education

Diabetes self-management education (DSMES): Referral to ADA-recognized DSMES program. ADA 2025 recommends DSMES at diagnosis, annually, and at times of complication.¹
Insulin technique and adherence: Proper injection technique, rotation sites, glucose monitoring, hypoglycemia recognition and treatment (the 15-15 rule).
Blood pressure monitoring: Home BP monitoring twice daily; sodium restriction; DASH diet; importance of medication adherence.
Weight management: Explain that 5–10% weight loss improves HbA1c by ~0.6–1.0%, lowers BP, and reduces OSA severity.³
OSA education: Explain OSA symptoms, metabolic consequences, and importance of testing. Discuss CPAP benefits. Emphasize risks of benzodiazepine use in this context.⁷
Epilepsy safety: Driving restrictions per state regulations; bath and swimming safety; seizure action plan for household members; importance of AED adherence.
Medication education: Never abruptly stop valproate or benzodiazepines. GLP-1 RA administration and storage. Side effects of new medications.

Preventive Care: Screening Recommendations

USPSTF-Recommended Screenings

Age- and Risk-Appropriate Screening for This Patient

Screening	Recommendation	Action
Cervical cancer	Pap + HPV co-test every 5 years, ages 30–65 (Grade A)²¹	Verify date of last screen
Breast cancer	Mammography every 2 years, ages 40–74 (Grade B, updated 2024)²²	Order if not done in 2 years
Colorectal cancer	Ages 45–75 (Grade A); FIT, colonoscopy, or stool DNA (2021)²³	Order FIT or refer for colonoscopy
Obesity counseling (BMI ≥30)	Intensive multicomponent behavioral intervention (Grade B)³	Refer to structured weight loss program
Depression	Annual PHQ-9 screening in adults (Grade B)⁶	Administer PHQ-9 today
Anxiety	Annual GAD-7 for adults <65 (Grade B, 2023)⁶	Administer GAD-7 today
Dyslipidemia / CVD prevention	Statin for CVD prevention in T2DM, ages 40–75 (Grade B)²⁴	Obtain fasting lipids; calculate ASCVD risk
T2DM monitoring	Already diagnosed; ADA 2025 annual monitoring panel¹	Annual HbA1c, UACR, eGFR, lipids, foot / eye exam

CDC/ACIP Vaccination Recommendations

Adult Immunization Schedule — Patient-Specific Actions

Vaccine	Recommendation	Action
Influenza	Annual for all adults (ACIP)	Administer today or document refusal
COVID-19	Updated annual booster per CDC 2024–2025 guidance²⁵	Confirm up to date
Pneumococcal (PCV20)	Single dose PCV20 for adults with T2DM (ACIP 2022); replaces prior PCV13 + PPSV23 series²⁵	Administer if not previously given
Tdap / Td	Tdap once (if not given); Td booster every 10 years	Review records; administer if due
Hepatitis B	3-dose series for unvaccinated adults <60; shared decision ≥60 (ACIP 2022)²⁵	Check anti-HBs; vaccinate if non-immune
Zoster (Shingrix)	2-dose series for adults ≥50 (ACIP; 97% efficacy in ages 50–69)²⁵	Schedule; 2–6 months between doses
Hepatitis A	2-dose series if unvaccinated and at risk	Assess risk factors and counsel

Follow-Up Plan

Sequenced Follow-Up Cadence

Timeframe	Priority Actions
2–4 weeks	Re-check BP after losartan uptitration; BMP; review glucose log; assess bromazepam taper progress; confirm HSAT / sleep medicine referral.
3 months	Repeat HbA1c; CBC and anemia workup results; HSAT / sleep study results; GLP-1 RA titration; PHQ-9 and GAD-7 reassessment; valproate level if indicated.
6 months	Review fasting lipid panel; ASCVD risk calculation; CPAP compliance assessment if applicable; weight and BMI trend; medication reconciliation; FIB-4 result review.
12 months	Annual: dilated eye exam, UACR / eGFR, foot exam, LFTs, HbA1c, fasting lipids, CBC; valproate drug level; full preventive care and immunization review; consider neurology reassessment for AED optimization.

Practice Point

Multimorbidity care is sequencing care. Address OSA and bromazepam first — without that, antihypertensive uptitration, glycemic intensification, and AED transition all carry avoidable risk. Anchor every visit to a re-prioritized problem list, not the chronologic chart.

References

[1]

American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1):S1–S352.

[2]

Whelton PK, Carey RM, Mancia G, et al. 2024 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Diagnosis and Management of Hypertension in Adults. Hypertension. 2024;81(6):e41–e109.

[3]

US Preventive Services Task Force. Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions. JAMA. 2023;329(12):1021–1031.

[4]

Chung F, Abdullah HR, Liao P. STOP-Bang Questionnaire: A Practical Approach to Screen for Obstructive Sleep Apnea. Chest. 2016;149(3):631–638.

[5]

Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An AASM Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479–504. Updated guidance 2023.

[6]

US Preventive Services Task Force. Screening for Anxiety Disorders in Adults: USPSTF Recommendation Statement. JAMA. 2023;329(24):2163–2170.

[7]

Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive Sleep Apnea: A Cardiometabolic Risk in Obesity and the Metabolic Syndrome. J Am Coll Cardiol. 2013;62(7):569–576.

[8]

Hall JE, do Carmo JM, da Silva AA, et al. Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms. Circ Res. 2015;116(6):991–1006.

[9]

Peppard PE, Young T, Barnet JH, et al. Increased Prevalence of Sleep-Disordered Breathing in Adults. Am J Epidemiol. 2013;177(9):1006–1014.

[10]

Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An AASM Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–349.

[11]

Ben-Menachem E. Weight Issues for People with Epilepsy: A Review. Epilepsia. 2007;48(Suppl 9):42–49.

[12]

Short MW, Domagalski JE. Iron Deficiency Anemia: Evaluation and Management. Am Fam Physician. 2013;87(2):98–104.

[13]

Rinella ME, Lazarus JV, Ratziu V, et al. A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature (MASLD). Hepatology. 2023;78(6):1966–1986.

[14]

Marso SP, Bain SC, Consoli A, et al. (SUSTAIN-6 Investigators). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM. 2016;375(19):1834–1844.

[15]

Zinman B, Wanner C, Lachin JM, et al. (EMPA-REG OUTCOME Investigators). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM. 2015;373(22):2117–2128.

[16]

Brenner BM, Cooper ME, de Zeeuw D, et al. (RENAAL Investigators). Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. NEJM. 2001;345(12):861–869.

[17]

Jamerson K, Weber MA, Bakris GL, et al. (ACCOMPLISH Investigators). Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. NEJM. 2008;359(23):2417–2428.

[18]

Qaseem A, Kansagara D, Forciea MA, et al. (ACP Clinical Guidelines Committee). Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125–133.

[19]

Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE Evidence Review of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. Epilepsia. 2013;54(3):551–563.

[20]

Katzman MA, Bleau P, Blier P, et al. (Canadian Anxiety Guidelines Initiative Group). Canadian Clinical Practice Guidelines for the Management of Anxiety, Posttraumatic Stress and Obsessive-Compulsive Disorders. BMC Psychiatry. 2014;14(Suppl 1):S1. Updated CANMAT 2023.

[21]

US Preventive Services Task Force. Cervical Cancer: Screening. USPSTF Recommendation Statement. JAMA. 2018;320(7):674–686.

[22]

US Preventive Services Task Force. Breast Cancer: Screening. USPSTF Recommendation Statement (Updated 2024). JAMA. 2024;331(22):1918–1930.

[23]

US Preventive Services Task Force. Colorectal Cancer: Screening. USPSTF Recommendation Statement. JAMA. 2021;325(19):1965–1977.

[24]

US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease Events in Adults: USPSTF Recommendation Statement. JAMA. 2022;328(8):746–753.

[25]

Centers for Disease Control and Prevention / ACIP. Recommended Adult Immunization Schedule for Ages 19 Years or Older — United States, 2024–2025. MMWR Morb Mortal Wkly Rep. 2024.

Published in HMD MedDigest — Medicine, via pristina. For clinicians, physician-executives, & medical trainees.